Bausch Health Companies Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Bausch Health Companies Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $2.16B | Feb 28, 2018 |
| FY2017 | Sep 30, 2017 | $2.22B | Feb 28, 2018 |
| FY2017 | Jun 30, 2017 | $2.23B | Feb 28, 2018 |
| FY2017 | Mar 31, 2017 | $2.11B | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $2.40B | Feb 28, 2018 |
| FY2017 | Sep 30, 2016 | $2.48B | Feb 28, 2018 |
| FY2017 | Jun 30, 2016 | $2.42B | Feb 28, 2018 |
| FY2017 | Mar 31, 2016 | $2.37B | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $2.76B | Mar 1, 2017 |
| FY2016 | Sep 30, 2015 | $2.79B | Mar 1, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.27B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $9.63B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $8.76B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $8.12B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $8.43B | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $2.21B | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $2.14B | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $1.66B | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $2.01B | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $2.22B | Feb 24, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $157.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($46.00M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($592.00M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($225.00M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($948.00M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($560.00M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($1.79B) | Feb 23, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.81B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.55B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $963.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $454.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $450.00M | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | ($5.00M) | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $460.00M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | ($27.00M) | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $248.00M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | ($1.08B) | Feb 24, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.44B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.30B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $2.92B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $2.63B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.62B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $2.37B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $2.55B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $2.47B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $2.58B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $2.81B | Feb 20, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.40B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.60B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.03B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($728.00M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.43B | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $394.00M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $256.00M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $200.00M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $261.00M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $234.00M | Feb 24, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $397.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $337.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $215.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $218.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $269.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $302.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $270.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $157.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $171.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $235.00M | Feb 20, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.37B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $26.52B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $27.35B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $25.69B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $29.20B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $31.20B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $33.86B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $32.49B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $37.50B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $43.53B | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.99B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $26.85B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $27.43B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $25.43B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $29.24B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $30.59B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $32.73B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $29.68B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $31.55B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $40.27B | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($554.00M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($1.28B) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($1.02B) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($692.00M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($106.00M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $535.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $1.06B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $2.73B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $5.85B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $3.15B | Feb 28, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.27B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $11.09B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $11.18B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $11.55B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $12.46B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $13.04B | Feb 23, 2023 |
| FY2022 | Dec 31, 2019 | $13.13B | Feb 23, 2023 |
| FY2021 | Dec 31, 2018 | $13.14B | Feb 23, 2022 |
| FY2020 | Dec 31, 2017 | $15.59B | Feb 24, 2021 |
| FY2017 | Jan 1, 2017 | $15.79B | Feb 28, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.67B) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($9.82B) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($9.78B) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($9.19B) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($8.96B) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($8.01B) | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | ($7.45B) | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | ($5.66B) | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | ($2.73B) | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | ($5.13B) | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.31B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.18B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $947.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $564.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $582.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $605.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $3.24B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $721.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $720.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $542.00M | Feb 20, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.82B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $21.62B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $22.39B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $20.77B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $22.65B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $23.93B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $25.90B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $24.31B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $25.44B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $29.85B | Feb 28, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | (5) | Feb 23, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Feb 20, 2019 |
| FY2018 | Sep 30, 2018 | (1) | Feb 20, 2019 |
| FY2018 | Jun 30, 2018 | (2) | Feb 20, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | (5) | Feb 23, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Feb 20, 2019 |
| FY2018 | Sep 30, 2018 | (1) | Feb 20, 2019 |
| FY2018 | Jun 30, 2018 | (2) | Feb 20, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 370.53M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 367.84M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 365.24M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 361.90M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 359.41M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 355.42M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | 352.56M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 349.87M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | 348.71M | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | 347.82M | Feb 28, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2010 | $356.29M | Feb 28, 2013 |
| FY2010 | Dec 31, 2009 | $147.15M | Feb 28, 2011 |
| FY2010 | Dec 31, 2008 | $180.29M | Feb 28, 2011 |